CN105288322A - Pharmaceutical composition for treating secretory otitis media - Google Patents
Pharmaceutical composition for treating secretory otitis media Download PDFInfo
- Publication number
- CN105288322A CN105288322A CN201510903104.8A CN201510903104A CN105288322A CN 105288322 A CN105288322 A CN 105288322A CN 201510903104 A CN201510903104 A CN 201510903104A CN 105288322 A CN105288322 A CN 105288322A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- otitis media
- secretory otitis
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating secretory otitis media. The pharmaceutical composition is prepared from the following traditional Chinese medicinal raw materials in parts by weight: 21-30 parts of babylon weeping willow root-bark, 9-15 parts of dandelion, 21-30 parts of rhizoma phragmitis, 5-8 parts of pomegranate blossom, 5-8 parts of mulberry leaves and 5-8 parts of centipeda minima. The pharmaceutical composition has a remarkable curative effect for treating secretory otitis media with western medical operation treatment, has a total effective rate of over 90 percent, and can be used for greatly shortening the treatment time and preventing relapse after healing.
Description
Technical field
The invention belongs to technical field of Chinese medicine, be specifically related to a kind of pharmaceutical composition for the treatment of secretory otitis media.
Background technology
The middle ear nonsuppurative inflammation disease that secretory otitis media is is feature with middle ear effusion and auditory dysesthesia, its cause of disease is complicated, and relevant etiology and pathogenetic research at present progressively deeply.Etiological is Eustachian tube disfunction, infect, immunoreation, stomach-esophageal reflux etc. (Kong Weijia. ENT & HN Surgery Dept. [M]. the 2nd edition. Beijing: People's Health Publisher, 2013:116-120.), wherein ETD is its principal pathogenetic basis, think that any reason causes pharyngotympanic tube to block wholly or in part, cause tympanum negative pressure, under the impact of negative pressure, there is expansion in the vein in middle-ear mucosa, tube wall permeability increases, serum spills and builds up in middle ear, form middle ear effusion, and middle ear effusion is the principal element causing auditory dysesthesia.Therefore, the negative pressure that clinical middle employing tympanum cuts and the way of pharyngotympanic tube catheterization alleviates middle ear can make patient produce quick, of short duration hearing improved.When to blow, the negative pressure in tympanum is just balanced or becomes malleation, and can return to the normal condition that can carry out gas exchange through the middle-ear mucosa of ventilation.But pharyngotympanic tube catheterization is many in transience effect, the gas be blown into likely is absorbed very soon, therefore have the necessity (Kaneko, Y., the Takasaka that repeatedly blow and open, T., Sakuma, M., etal.Middleearinflationasatreatmentforsecretoryotitismed iainchildren [J] .ActaOtolaryngol, 1997,177 (11): 567.).
At present, western medical treatment secretory otitis media is taked to remove middle ear effusion, improve MEV function, whole body therapeutic and the principle for etiological treatment more, Main Means is medicine and operation, as the method for antibiotic, nasal decongestant, steroid hormone, application puncture into tympanic cavity drawing liquid, though achieve certain effect, but curative effect is not ideal enough, and the state of an illness easily recurs.
Summary of the invention
In view of the dissatisfactory problem of western medical treatment effect, the object of the present invention is to provide a kind of Chinese medicine composition for the treatment of secretory otitis media.The object of the present invention is achieved like this:
Treat a pharmaceutical composition for secretory otitis media, be made up of the traditional Chinese medicinal material raw materials of following weight portion: Cortex Salicis Babylonicae Radicis 21-30 part, Herba Taraxaci 9-15 part, Rhizoma Phragmitis 21-30 part, Flos Granati 5-8 part, Folium Mori 5-8 part, Herba Centipedae 5-8 part.
Preferably, the pharmaceutical composition for the treatment of secretory otitis media is made up of the traditional Chinese medicinal material raw materials of following weight portion as mentioned above: Cortex Salicis Babylonicae Radicis 24-26 part, Herba Taraxaci 11-13 part, Rhizoma Phragmitis 24-26 part, Flos Granati 6-8 part, Folium Mori 6-8 part, Herba Centipedae 6-8 part.
In the present invention's most preferred embodiment, the pharmaceutical composition for the treatment of secretory otitis media is made up of the traditional Chinese medicinal material raw materials of following weight portion as mentioned above: Cortex Salicis Babylonicae Radicis 25 parts, Herba Taraxaci 12 parts, Rhizoma Phragmitis 25 parts, Flos Granati 7 parts, 7 parts, Folium Mori, Herba Centipedae 7 parts.
The pharmaceutical composition of any one treatment secretory otitis media above-mentioned, it can be made into oral liquid, granule, tablet, capsule; Preferably, the pharmaceutical composition of any one treatment secretory otitis media above-mentioned, it is made into oral liquid.
It should be noted that, traditional Chinese medicinal material raw materials source of the present invention is as follows: Cortex Salicis Babylonicae Radicis selects the bark of Salicaceous Plants Salix babylonica L. SalixbabylonicaL.; Herba Taraxaci selects the dry herb of feverfew Herba Taraxaci TaraxacummongolicumHand.-Mazz.; Rhizoma Phragmitis selects the dry rhizome of grass phragmites communis PhragmitescommunisTrin.; Flos Granati selects the dry flower of Punicaceae plant Punica granatum L. PunicagranatumL.; Folium Mori select the dried leaves of moraceae plants Mulberry MorusalbaL.; Herba Centipedae selects the dry herb of feverfew Herba Centipedae Centipedaminima (L.) A.Br.etAschers..
Compared with prior art, the pharmaceutical composition that the present invention relates to coordinates the evident in efficacy of doctor trained in Western medicine operative treatment secretory otitis media disease, and total effective rate reaches more than 90%, and treatment time significantly shortens simultaneously, does not recur more.
Detailed description of the invention
Be below specific embodiments of the invention and clinical practice example, technical scheme of the present invention and technique effect are done and describes further, but protection scope of the present invention be not limited to these embodiments.Every do not deviate from the present invention's design change or equivalent substituting include within protection scope of the present invention.
The preparation of embodiment 1 Chinese medicine oral liquid
Crude drug prescription: Cortex Salicis Babylonicae Radicis 25kg, Herba Taraxaci 12kg, Rhizoma Phragmitis 25kg, Flos Granati 7kg, Folium Mori 7kg, Herba Centipedae 7kg.
Preparation technology:
(1) get the Cortex Salicis Babylonicae Radicis of recipe quantity, Herba Taraxaci, Rhizoma Phragmitis, Flos Granati, Folium Mori and Herba Centipedae, remove impurity is for subsequent use;
(2) above-mentioned medical material is added water cover powder 2cm, soak 1-1.2h, pull medical material out and put during multi-functional extractions is filled with and decoct with water secondary, first time totalling medical material 8 times amount water, decoct 2h, get decocting liquid, filter, second time adds up the water of medical material 8 times amount, decoct 1.5h, get twice decocting liquid to merge, filter, when being concentrated into 90 DEG C, relative density is the concentrated solution of 1.15;
(3) concentrated solution is put 3-5 DEG C of deepfreeze 24h, cold preservation liquid is added the filter aid kieselguhr of 0.3%, filter, filtrate reconcentration containing 2g crude drug amount, puts 3-5 DEG C of deepfreeze 24h to every milliliter, is filtered by cold preservation liquid, packs and obtain oral liquid.
The preparation of embodiment 2 Chinese medicine oral liquid
Crude drug prescription: Cortex Salicis Babylonicae Radicis 21kg, Herba Taraxaci 15kg, Rhizoma Phragmitis 30kg, Flos Granati 8kg, Folium Mori 8kg, Herba Centipedae 6kg.
Preparation technology:
(1) get the Cortex Salicis Babylonicae Radicis of recipe quantity, Herba Taraxaci, Rhizoma Phragmitis, Flos Granati, Folium Mori and Herba Centipedae, remove impurity is for subsequent use;
(2) above-mentioned medical material is added water cover powder 2cm, soak 1-1.2h, pull medical material out and put during multi-functional extractions is filled with and decoct with water secondary, first time totalling medical material 10 times amount water, decoct 2h, get decocting liquid, filter, second time adds up the water of medical material 8 times amount, decoct 1.5h, get twice decocting liquid to merge, filter, when being concentrated into 90 DEG C, relative density is the concentrated solution of 1.15;
(3) concentrated solution is put 3-5 DEG C of deepfreeze 24h, cold preservation liquid is added the filter aid kieselguhr of 0.3%, filter, filtrate reconcentration containing 2g crude drug amount, puts 3-5 DEG C of deepfreeze 24h to every milliliter, is filtered by cold preservation liquid, packs and obtain oral liquid.
The preparation of embodiment 3 Chinese medicine oral liquid
Crude drug prescription: Cortex Salicis Babylonicae Radicis 26kg, Herba Taraxaci 15kg, Rhizoma Phragmitis 21kg, Flos Granati 8kg, Folium Mori 8kg, Herba Centipedae 8kg.
Preparation technology:
(1) get the Cortex Salicis Babylonicae Radicis of recipe quantity, Herba Taraxaci, Rhizoma Phragmitis, Flos Granati, Folium Mori and Herba Centipedae, remove impurity is for subsequent use;
(2) above-mentioned medical material is added water cover powder 2cm, soak 1-1.2h, pull medical material out and put during multi-functional extractions is filled with and decoct with water secondary, first time totalling medical material 10 times amount water, decoct 2h, get decocting liquid, filter, second time adds up the water of medical material 8 times amount, decoct 1h, get twice decocting liquid to merge, filter, when being concentrated into 90 DEG C, relative density is the concentrated solution of 1.15;
(3) concentrated solution is put 3-5 DEG C of deepfreeze 24h, cold preservation liquid is added the filter aid kieselguhr of 0.3%, filter, filtrate reconcentration containing 2g crude drug amount, puts 3-5 DEG C of deepfreeze 24h to every milliliter, is filtered by cold preservation liquid, adds correctives and packs and obtain oral liquid.
Embodiment 4 Chinese medicine oral liquid is to the effectiveness study of patients with secretory otitis media
Patients with secretory otitis media 47 example of clinical definite, clinical manifestation is that ear is vexed, auditory dysesthesia, tinnitus; Check that visible tympanum is matt, light cone disappears, in oil immersion shape, and visible oily plane sometimes; Pure tone test Air-bone gap is about < 40dB (HL), and acoustic impedance check result is " B " type tympanum Figure 44 ear, " C " type tympanogram 8 ear; All patients, all in the descending myringotomy of endotoscpe, see pale yellow transparent thin liquid 42 ear in art, faint yellow thick liquid 10 ear.
47 routine patients are divided into observation group and matched group by randomly assigne.Observation group 24 example (26 ear), male 13 examples (15 ear), female 11 example (11 ear); 19 ~ 63 years old age, average (38.5 ± 4.2) year, course of disease two weeks ~ 7 month, average (2.9 ± 0.2) individual month.Matched group 23 example (26 ear), male 12 examples (14 ear), female 11 example (12 ear), 20 ~ 65 years old age, average (37.7 ± 5.0) year, course of disease two weeks ~ 6 month, average (3.0 ± 0.2) individual month.The physical data such as sex, trouble ear number, age, the course of disease of two groups of patients compares there was no significant difference, has comparability.
All patients all under topical anesthesia through the capable myringotomy of endotoscpe.Concrete grammar: allow patient's central seats that directly face the stage on diagnosis chair, 15min is about with being soaked with 2% tetracaine liquid cotton piece on tympanum surface, debug endotoscpe system, radial incision is made at tympanum anteroinferior quadrant, be about 2mm, during operation, action is soft, excessively not dark, in order to avoid important feature such as damage mucosa of tympanic cavity and auditory ossicles etc.Postoperative oral amoxicillin capsule anti-inflammatory treatment 3d.Observation group adds with Chinese medicine oral liquid of the present invention (preparing by the formulation and technology of embodiment 1) treatment again except above-mentioned treatment, and sooner or later respectively once, each 40mL, continues 2 weeks altogether.After treatment terminates, evaluate two groups of patient clinical curative effects by following curative effect determinate standard:
Cure: the transference cures such as the vexed swollen sense of ear, auditory dysesthesia, tinnitus, check that tympanum is glossy, light cone is visible, each frequency threshold of audibility of pure tone test reverts to < 15dB (HL); Tympanometry, tympanogram curve is " A " type.
Effective: tinnitus, the vexed swollen sense of ear, auditory dysesthesia alleviate, check that tympanum activity is slightly poor, each frequency of pure tone test (500 ~ 2000Hz) is about 20dB (HL) for < 25dB (HL), each mean frequency value; Tympanometry, tympanum pressure makes moderate progress, and tympanogram curve is " A " type or " B " type ripple.
Invalid: the symptoms such as tinnitus, the vexed swollen sense of ear, auditory dysesthesia are without improvement, and pure tone test each frequency threshold of audibility average is without improvement, and tympanogram curve is still " B " type or " C " type.
Two groups of patient clinical comparitive study are in table 1.Can be found out by the test statistics result of table 1, matched group cure rate is 15.4%, total effective rate 34.6%; Test group cure rate is 42.3%, total effective rate 92.3%, and obvious test group clinical efficacy is better than matched group.
Table 1 liang group patient clinical comparitive study (ear)
Claims (6)
1. treat a pharmaceutical composition for secretory otitis media, it is characterized in that: it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Cortex Salicis Babylonicae Radicis 21-30 part, Herba Taraxaci 9-15 part, Rhizoma Phragmitis 21-30 part, Flos Granati 5-8 part, Folium Mori 5-8 part, Herba Centipedae 5-8 part.
2. treat the pharmaceutical composition of secretory otitis media according to claim 1, it is characterized in that: it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Cortex Salicis Babylonicae Radicis 24-26 part, Herba Taraxaci 11-13 part, Rhizoma Phragmitis 24-26 part, Flos Granati 6-8 part, Folium Mori 6-8 part, Herba Centipedae 6-8 part.
3. treat the pharmaceutical composition of secretory otitis media according to claim 2, it is characterized in that: it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Cortex Salicis Babylonicae Radicis 25 parts, Herba Taraxaci 12 parts, Rhizoma Phragmitis 25 parts, Flos Granati 7 parts, 7 parts, Folium Mori, Herba Centipedae 7 parts.
4. according to claim 1 or 2 or 3, treat the pharmaceutical composition of secretory otitis media, it is characterized in that: this pharmaceutical composition is oral formulations.
5. treat the pharmaceutical composition of secretory otitis media according to claim 3, it is characterized in that: described oral formulations comprises oral liquid, granule, tablet, capsule.
6. claim 1 or the traditional Chinese medicinal material raw materials compositions described in 2 or 3 application in the medicine of preparation treatment secretory otitis media.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510903104.8A CN105288322A (en) | 2015-12-09 | 2015-12-09 | Pharmaceutical composition for treating secretory otitis media |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510903104.8A CN105288322A (en) | 2015-12-09 | 2015-12-09 | Pharmaceutical composition for treating secretory otitis media |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105288322A true CN105288322A (en) | 2016-02-03 |
Family
ID=55186600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510903104.8A Pending CN105288322A (en) | 2015-12-09 | 2015-12-09 | Pharmaceutical composition for treating secretory otitis media |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105288322A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813917A (en) * | 2005-11-26 | 2006-08-09 | 安徽省药物研究所 | Medicine for treating acute secretory tympanitis and its preparing method |
| CN102670721A (en) * | 2012-05-28 | 2012-09-19 | 张英耀 | Traditional Chinese medicine preparation for curing secretory otitis media and preparation method thereof |
-
2015
- 2015-12-09 CN CN201510903104.8A patent/CN105288322A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813917A (en) * | 2005-11-26 | 2006-08-09 | 安徽省药物研究所 | Medicine for treating acute secretory tympanitis and its preparing method |
| CN102670721A (en) * | 2012-05-28 | 2012-09-19 | 张英耀 | Traditional Chinese medicine preparation for curing secretory otitis media and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 李云英等: "《中西医结合耳鼻咽喉口齿科学》", 31 August 2003, 科学出版社 * |
| 温梦霞: "《传世药膳方》", 31 July 2015, 福建科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100471509C (en) | Medicine for treating tympanitis and otitis externa, and preparing method | |
| CN103230513B (en) | A kind of Chinese drug-treated group mixture for the treatment of acute and chronic rhinitis and preparation method thereof | |
| CN103520409B (en) | A kind of Chinese medicine preparation for the treatment of secretory otitis media and preparation method thereof | |
| CN108853346A (en) | A kind of external-applied ointment for treating cheilitis | |
| CN108283708A (en) | A kind of pharmaceutical composition and preparation method thereof for treating acute rhinitis and chronic and allergic rhinitis | |
| CN105288322A (en) | Pharmaceutical composition for treating secretory otitis media | |
| CN107308305B (en) | Preparation for treating infantile eczema, dermatitis and infantile eczema | |
| CN104398898A (en) | Preparation method for climacteric hyperthyroidism ion penetration agent | |
| CN110721303A (en) | Traditional Chinese medicine composition for treating allergic rhinitis and application thereof | |
| CN104382974A (en) | Medicament composition for treating chronic otitis media and preparation method thereof | |
| CN102579777A (en) | Preparation method of Chinese medicinal lotion for treating chronic ulcer of shank with itching syndrome | |
| CN102614357A (en) | Preparation method of traditional Chinese medicine lotion for treating lumbago type lumbago | |
| CN108186829B (en) | Chinese herbal medicine composition for treating chronic rhinitis and preparation method thereof | |
| CN102614362B (en) | Preparation method for traditional Chinese medicine lotion for treating smoking type ecthyma | |
| CN104825809A (en) | Medicament for treating peripheral facial paralysis | |
| CN104840823A (en) | Traditional Chinese medicine preparation for treating otitis media and preparation method | |
| CN104398899A (en) | Penetration ion suitable for climacteric hyperthyroid patients | |
| CN105079488A (en) | Traditional Chinese medicine for treating whitlow, and preparation method thereof | |
| CN103893509B (en) | A kind of medicine for the treatment of of allergic rhinitis and preparation method | |
| CN104740114A (en) | Traditional Chinese medicine composition for treating secretory otitis media | |
| CN104435133A (en) | Medicament for reducing fever | |
| CN104524175A (en) | Traditional Chinese medicine composition for treating acute conjunctivitis | |
| CN106511768A (en) | Pharmaceutical composition for preventing and treating tympanitis and preparation method thereof | |
| CN108498643A (en) | A kind of Chinese medicine for treating nasosinusitis | |
| CN108339030A (en) | A kind of Chinese medicine for treating nasosinusitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |
|
| WD01 | Invention patent application deemed withdrawn after publication |